A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer

作者：Huang Jiayi; Baschnagel Andrew M; Chen Peter; Gustafson Gregory; Jaiyesmi Ishmael; Folbe Mitchell; Ye Hong; Akervall Jan; Krauss Daniel^*

来源：International Journal of Clinical Oncology, 2014, 19(2): 240-246.

DOI：10.1007/s10147-013-0540-y

• Head neck cancer
• Chemoradiotherapy
• cetuximab
• Cisplatin
• IMRT

We retrospectively compared the efficacy of intensity-modulated radiotherapy (IMRT) and cetuximab (IMRT/cetuximab) versus IMRT and platinum-based chemotherapy (IMRT/platinum) for locally advanced head neck squamous cell carcinoma (LAHNSCC). %26lt;br%26gt;Thirty-one IMRT/cetuximab patients were matched 1:2 with 62 IMRT/platinum patients according to primary site and clinical stage. The primary endpoint was locoregional recurrence (LRR), and secondary endpoints included distant metastasis (DM), cause-specific survival (CSS), and overall survival (OS). %26lt;br%26gt;Because of inherent selection bias, the IMRT/cetuximab cohort was significantly older and with a higher Charlson Comorbidity Index. IMRT/cetuximab and IMRT/platinum did not have significantly different LRR and DM (33 vs. 23 % at 2 years, P = 0.22; 17 vs. 11 % at 2 years, P = 0.40; respectively). IMRT/cetuximab had significantly worse CSS and OS (67 vs. 84 %, P = 0.04; 58 vs. 83 %, P = 0.001; respectively). However, for the subset of elderly patients a parts per thousand yen65 years old, there is no difference between the two cohorts for all endpoints (all P = NS). %26lt;br%26gt;IMRT/platinum should remain the preferred choice of chemoradiotherapy for LAHNSCC, but IMRT/cetuximab may be a reasonable alternative for elderly patients.

• 出版日期2014-4